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Depot antipsychotic drugs, or long-acting injectable
antipsychotics (LAIs), have been available since the
1960s and were conceived mainly to improve adherence
to treatment in patients with schizophrenia. Even though
it is known that more than half of the patients with
schizophrenia do not properly comply with oral medica-
tion treatments1 and that LAIs are the best choice for
such cases, the prescription of these drugs has sig-
nificantly decreased over the years. Indeed, less than
30% of patients with schizophrenia are currently treated
with LAIs.2
There is a widespread belief that LAIs have more and
even worse adverse effects than their equivalent oral
preparations. Although there is support for this notion in
the literature,3 a recent review of randomized controlled
studies has shown that, whereas some of the LAIs
currently available may cause similar or more severe side
effects, others such as risperidone have similar or even
milder side-effect profiles than their oral counterparts.4
In addition, because LAIs have been used over the
past 50 years, many psychiatrists consider that they are
‘‘old-fashioned’’ drugs. Notwithstanding, the fact is that
second-generation LAIs such as risperidone became
available in 2002, and paliperidone palmitate was only
recently released in the market, in 2009.5
Recent evidence has shown that LAIs are more
effective in preventing both relapse and re-hospitalization
when compared with oral medications.2 Furthermore, the
availability of depot medication gives psychiatrists the
opportunity to readily identify non-adherence to treatment
and to reduce the risk of self-intoxication by inappropriate
medication use.2
A large body of clinical and neurobiological evidence
has shown that psychotic relapse is associated with brain
volume reductions and clinical deterioration. This effect is
particularly important in the years following the first
psychotic episode. Psychiatrists usually consider LAIs
as their last choice, after the occurrence of several
psychotic episodes, with their deleterious effects. Indeed,
LAIs are not commonly indicated for first-episode
psychosis, despite the high rates of non-adherence to
treatment observed in this group of patients.
Nevertheless, advantages of the use of LAIs have been
consistently reported, and studies have shown that the
risk of re-hospitalization for patients receiving depot
medications is about one-third of that for patients
receiving oral medications.6
Several studies have shown that the prevention of
psychotic relapse has major implications for the mini-
mization of damage and of some disabilities that typically
affect these individuals.7 In other words, the earlier the
pharmacological treatment is implemented, the better the
prognosis. In this context, the use of depot antipsychotics
could provide psychiatrists with the assurance that this
window of opportunity would not be missed, especially in
the initial phase of the disease - up to 5 years after the
onset of psychotic symptoms -, a critical period for
prognosis.
We expect that the attitudes of mental health profes-
sionals towards the use of LAIs become more based on
facts than on myths. In this way, perhaps, misconceptions
regarding depot antipsychotic drugs could be mitigated.
Why aren’t we prescribing LAIs more often? This is the
question we all should ask ourselves.
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